SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease

Brain

Volumn 133, Issue 7, 2010, Pages 2032-2044

  Garcia Reitböck, Pablo ^a   Anichtchik, Oleg ^a   Bellucci, Arianna ^b   Iovino, Mariangela ^a   Ballini, Chiara ^c   Fineberg, Elena ^a   Ghetti, Bernardino ^d   Della Corte, Laura ^c   Spano, Pierfranco ^b   Tofaris, George K ^e   Goedert, Michel ^f   Spillantini, Maria Grazia ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

alpha synuclein; dopamine; neurodegenerative diseases; Parkinson's disease; SNARE proteins

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; SNARE PROTEIN; SYNAPTOBREVIN 2; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; ENZYME ACTIVITY; EXOCYTOSIS; MOUSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYNAPSE; TRANSGENIC MOUSE;

EID: 77954379317     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq132     Document Type: Article

References (42)

1. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002; 22: 9340-9351
2. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 2009; 118: 167-179
3. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998; 152: 879-884
4. Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P. Alphasynuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. J Neurochem 2008; 106: 560-577
5. Chandra S, Gallardo G, Fernandez-Chacon R, Schlüter OM, Südhof TC. Alpha-synuclein cooperates with CSPα in preventing neurodegeneration. Cell 2005; 123: 383-396
6. Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV α-synucleinopathy. J Neurosci 2009; 29: 3365-3373
7. Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett 1998; 436: 309-312
8. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002; 99: 14524-14529
9. Dunkley PR, Jarvie PE, Robinson PJ. A rapid Percoll gradient procedure for preparation of synaptosomes. Nat Protoc 2008; 3: 1718-1728
10. + toxicity in models of human neurons. Eur J Neurosci 2008; 28: 2459-2473
11. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-4.
12. Gaffield MA, Betz WJ. Imaging synaptic vesicle exocytosis and endocytosis with FM dyes. Nat Protoc 2006; 1: 2916-2921
13. Gardner PR. Aconitase: sensitive target and measure of superoxide. Methods Enzymol 2002; 349: 9-23.
14. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001; 2: 492-501.
15. Greffard S, Verny M, Bonnet AM, Seilhear D, Hauw JJ, Duyckaerts C. A stable proportion of Lewy body-bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging 2010; 31: 99-103.
16. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998; 51: S2-9.
17. Ibanez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364: 1169-1171
18. Kay AR, Alfonso A, Alford S, Cline HT, Holgado AM, Sakmann B, et al. Imaging synaptic activity in intact brain and slices with FM1-43 in C. elegans, lamprey and rat. Neuron 1999; 24: 809-817
19. Kisselev AF, Goldberg AL. Monitoring activity and inhibition of 26S proteasome with fluorogenic peptide substrate. Methods Enzymol 2005; 398: 364-378
20. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27: 1405-1410
21. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet 1998; 18: 106-108
22. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, et al. α-Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006; 26: 11915-11922
23. Liu CW, Giasson BI, Lewis KA, Lee VM, DeMartino GN, Thomas PJ. A precipitating role for truncated α-synuclein and the proteasome in α-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 2005; 280: 22670-22678
24. McMahon HT, Missler M, Li C, Südhof TC. Complexins: cytosolic proteins that regulate SNAP receptor function. Cell 1995; 83: 111-119
25. Magnani E. Molecular physiology and pathology of tau protein interactions. PhD thesis. University of Cambridge, 2006.
26. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
27. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al. Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008; 131: 642-650
28. Paxinos G, Franklin K. The mouse brain in stereotaxic coordinates. San Diego: Academic Press; 2001.
29. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007; 27: 3338-3346
30. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in α-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047
31. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791
32. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-ß conformation. Proc Natl Acad Sci USA 2000; 97: 4897-4902
33. Sidhu A, Wersinger C, Vernier P. Does α-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 2004; 18: 637-647
34. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
35. Specht CG, Schoepfer R. Deletion of the alpha-synuclein locus in a sub-population of C57BL/6J inbred mice. BMC Neurosci 2001; 2: 11-19.
36. Spillantini MG, Speretta E, Goedert M, Magnani E. Tau and alpha-synuclein interaction in neurodegenerative diseases. Neurodeg Dis 2007; 4 (Suppl 1): 185.
37. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-6473 (Pubitemid 28249037)
38. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997; 338: 839-840
39. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003; 278: 44405-44411
40. Tofaris GK, Reitböck PG, Humby T, Lambourne SL, O'Connell M, Ghetti B, et al. Pathological changes in dopaminergic neurons in mice transgenic for human α-synuclein (1-120): implications for Lewy body disorders. J Neurosci 2006; 26: 3942-3950
41. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation E46K of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-173
42. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease. A mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci 2008; 1147: 93-104.